Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: Effects of anti-TNFα treatment

Antonio Di Sabatino, Francesca Santilli, Marco Guerci, Paola Simeone, Sandro Ardizzone, Alessandro Massari, Paolo Giuffrida, Romina Tripaldi, Alessandro Malara, Rossella Liani, Evelyn Gurini, Nicola Aronico, Alessandra Balduini, Gino Roberto Corazza, Giovanni Davì

Research output: Contribution to journalArticlepeer-review


Patients with inflammatory bowel disease (IBD) are at higher risk of venous thromboembolism and coronary artery disease despite having a lower burden of traditional risk factors. Platelets from IBD patients release more soluble CD40 ligand (CD40L), and this has been implicated in IBD platelet hyper-activation. We here measured the urinary F2-isoprostane 8-iso-prostaglandin (PG) (8-iso-PGF), urinary 11–dehydro–thromboxane (TX) B2 (11-dehydro–TXB2) and plasma CD40L in IBD patients, and explored the in vitro action of anti-tumour necrosis factor (TNF)– α antibody infliximab on IBD differentiating megakaryocytes. Urinary and blood samples were collected from 124 IBD patients and 37 healthy subjects. Thirteen IBD patients were also evaluated before and after 6–week infliximab treatment. The in vitro effect of infliximab on patient-derived megakaryocytes was evaluated by immunoflorescence microscopy and by flow cytometry. IBD patients had significantly (p<0.0001) higher urinary 8–iso–PGF and 11–dehydro–TXB2 as well as plasma CD40L levels than controls, with active IBD patients displaying higher urinary and plasma values when compared to inactive patients in remission. A 6-week treatment with infliximab was associated with a significant reduction of the urinary excretion of 8–iso–PGF and 11–dehydro–TXB2 (p=0.008) and plasma CD40L (p=0.001). Infliximab induced significantly rescued pro-platelet formation by megakaryocytes derived from IBD patients but not from healthy controls. Our findings provide evidence for enhanced in vivo TX–dependent platelet activation and lipid peroxidation in IBD patients. Anti-TNF– α therapy with infliximab down-regulates in vivo isoprostane generation and TX biosynthesis in responder IBD patients. Further studies are needed to clarify the implication of infliximab induced-proplatelet formation from IBD megakaryocytes.

Original languageEnglish
Pages (from-to)486-495
Number of pages10
JournalThrombosis and Haemostasis
Issue number3
Publication statusPublished - 2016


  • CD40 ligand
  • Crohn’s disease
  • Infliximab
  • Lipid peroxidation
  • Platelet activation
  • Ulcerative colitis

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: Effects of anti-TNFα treatment'. Together they form a unique fingerprint.

Cite this